Nearly 20 percent of kidneys that are recovered from deceased donors in the U.S. are refused for transplant due to factors ranging from scarring in small blood vessels of the kidney’s filtering units to the organ going too long without blood or oxygen. But, what if instead of being discarded, these organs could be “recycled” to help solve the critical shortage of donor organs?
Scientists at UC Santa Barbara have demonstrated in the laboratory that a new drug is effective in treating a very common kidney disease ?? although it will be a few years before it becomes available for clinical testing. The findings resulted from a collaboration between UCSB and a biotech firm based in Indiana. The study is published in this week’s Journal of the American Society of Nephrology.
Researchers at the Translational Genomics Research Institute (TGen) have developed a method of isolating biospecimens that could lead to a less costly, less invasive and more accurate way of diagnosing chronic kidney disease, or CKD.
In findings that may lead to clinical trials of a promising new drug for kidney disease, researchers at Beth Israel Deaconess Medical Center (BIDMC) and their colleagues have identified a key molecular player and shown how a targeted experimental drug can reverse kidney damage in mouse models of diabetes, high blood pressure, genetic kidney disease, and other kidney injuries.
Damage to podocytes — a specialized type of epithelial cell in the kidney — occurs in more than 90 percent of all chronic kidney disease. Now researchers at the Stanford University School of Medicine have uncovered an unexpected pathway that reveals for the first time how these cells may regenerate and renew themselves during normal kidney function.
Nearly half of all adults over 20 will experience at least one lower urinary tract symptom by 2018 – an estimated 2.3 billion people and a worldwide increase of 18% in just one decade – according to research in the October issue of the urology journal BJUI.
High blood pressure, high blood sugar, abdominal fat, low good cholesterol may contribute to kidney disease
Metabolic syndrome comprises a group of medical disorders that increase people’s risk of diabetes, heart disease, stroke, and premature death when they occur together. A patient is diagnosed with the syndrome when he or she exhibits three or more of the following characteristics: high blood pressure, high blood sugar, excess body fat in the waist/abdomen, low good cholesterol, and higher levels of fatty acids (the building blocks of fat).
Hospital ClÃnic of Barcelona applied this proceeding for the first time in the world to living donors for kidney trasplant
This release is available in Spanish.
Reprogrammed kidney cells could make transplants and dialysis things of the past
- Patients’ own kidney cells can be reprogrammed and used as therapy against kidney disease
- Cells can easily be collected from the urine
- 88,000 patients are waiting for a kidney transplant in the United States, and they wait for an average of 3 to 5 years
(Santa Barbara, Calif.) — Two discoveries at UC Santa Barbara point to potential new drug therapies for patients with kidney disease. The findings are published in this week’s issue of the Proceedings of the National Academy of Sciences.